Immunotherapy plus targeted therapy before surgery for early lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving a combination of two drugs (sintilimab and anlotinib) before surgery can help shrink non-small cell lung cancer tumors and improve outcomes. It is for people with stage IB to IIIB cancer that can be removed with surgery and who have not had treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with non-small cell lung cancer (a common type of lung cancer).
- Your cancer is stage IB to IIIB and can be removed with surgery.
- You have not had any previous treatment for this cancer.
- Your tumor does not have certain genetic changes (EGFR, ALK, or ROS1 mutations).
- You are healthy enough for surgery and have good organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests whether giving more immunotherapy after surgery can help people with non-small cell lung cancer who still had some cancer cells left after their first round of immunotherapy and chemotherapy before surgery. It aims to improve outcomes for those whose tumor didn't fully disappear.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.